March 4, 2022: We write today to follow up on your response to several requests for information at the Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) Medical Device User Fee Amendments (MDUFA V) stakeholders meeting on February 28, 2022.
Read More »Tag: transparency
NCHR’s Comments on EPA’s Supplemental Notice of Proposed Rulemaking on Strengthening Transparency in Regulatory Science
There is no legitimate scientific basis for this proposal. It fails to improve transparency among the broader scientific community or between EPA and the public. We therefore strongly urge the rejection of this proposed rule and its expansions under the supplemental proposal.
Read More »